IL17A and breast cancer: A retrospective cohort study suggested that AS was not associated with an increased risk of BC diagnosis.[17] However, Feng et al found that high levels of interleukin (IL)-17 secreted in AS may act as a tumor-promoting factor for BC.[18] From a pathophysiological perspective, the biomarker IL-17 may be a common therapeutic target for both AS and BC.